Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-01-15
2001-07-31
Kunz, Gary L. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S327000
Reexamination Certificate
active
06268347
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to the field of pain therapy and more specifically to the use of prosaposin-derived peptides for the treatment of neuropathic pain.
2. Background Information
Neuropathic pain results from injury to a nerve. In contrast to the immediate pain caused by tissue injury, neuropathic pain can develop days or months after a traumatic injury. Furthermore, while pain caused by tissue injury is usually limited in duration to the period of tissue repair, neuropathic pain frequently is long-lasting or chronic. Moreover, neuropathic pain can occur spontaneously or as a result of stimulation that normally is not painful.
The clinical causes of neuropathic pain are widespread and include both trauma and disease. For example, traumatic nerve compression or crush and traumatic injury to the brain or spinal cord are common causes of neuropathic pain. Furthermore, most traumatic nerve injuries also cause the formation of neuromas, in which pain occurs as a result of aberrant nerve regenration. In addition, cancer-related neuropathic pain is caused when tumor growth painfully compresses adjacent nerves, brain or spinal cord. Neuropathic pain also is associated with diseases such as diabetes or alcoholism.
Unfortunately, neuropathic pain frequently is resistant to available drug therapies. In addition, current therapies have serious side-effects including, for example, cognitive changes, sedation, nausea and, in the case of narcotic drugs, addiction. Many patients suffering from neuropathic pain are elderly or have other medical conditions that particularly limit their tolerance of the side-effects associated with available drug therapy. The inadequacy of current therapy in relieving neuropathic pain without producing intolerable side-effects frequently is manifest in the depression and suicidal tendency of chronic pain sufferers.
Methods of alleviating neuropathic pain would improve the quality of life for many people suffering from pain due to trauma or disease. However, there currently are not effective drugs that relieve neuropathic pain without undesirable side-effects such as sedation and addiction. Thus, there is a need for methods of alleviating neuropathic pain without producing undesirable side-effects. The present invention satisfies this need and provides related advantages as well.
SUMMARY OF THE INVENTION
The present invention provides a method of alleviating neuropathic pain in a subject by administering an effective amount of an active fragment of prosaposin to the subject. For example, the invention provides a method of alleviating neuropathic pain resulting from a disorder of peripheral nerve, dorsal root ganglia, spinal cord, brain stem, thalamus or cortex in a subject by administering an effective amount of an active fragment of prosaposin having the amino acid sequence Cys—Flu—Phe—Leu—Val—Lys—Glu—Val—Thr—Lys—Leu—Ile—Asp—Asn—Asn—Lys—Thr—Glu—Lys—Glu—Ile—Leu (SEQ ID NO: 1) or Thr—D—Ala—Leu—Ile—Asp—Asn—Asn—Ala—Thr—Glu—Glu—Ile—Leu—Tyr (SEQ ID NO: 2). In addition, the invention provides a method of preventing neuropathic pain in a subject by administering an effective amount of an active fragment of prosaposin to the subject.
REFERENCES:
patent: 5470582 (1995-11-01), Supersaxo et al.
patent: 5571787 (1996-11-01), O'Brien et al.
patent: 5700909 (1997-12-01), O'Brien
patent: 0246753 A2 (1987-11-01), None
Bennett, “An Animal Model of Neuropathic Pain: A Review”,Muscle and Nerve(Oct. 1993) 16:1010-1048.
Bennett, “Neuropathic Pain”,Textbook of Painpp. 201-224 (1994).
Bonica & Butler, “Local anesthesia and regional blocks”Textbook of Painpp. 997-1023 (1994).
Botney & Fields, “Amitriptyline Potentiates Morphine Analgesia by a Direct Action on the Central Nervous System”Ann. Neurol.13(2):160-164, (1983).
Calcutt et al., “Different effect of two aldose reductase inhibitors on noniception and prostaglandin E”Eur. J. Pharmacol.285:189-197, (1995).
Calcutt et al., “Tactile allodynia and formal in hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine”Pain 68:293-299 (1996).
Calcutt et al. “Tolrestat treatment prevents modification of the formalin test model of prolonged pain in hyperglycemic rats”,Pain 58:413-420, (1994).
Campana et al., “Induction of MAPK Phosphorylation by Prosapos in and Prosaptide in PC12 Cells”Biochem. Biophys. Res. Comm.229(3):706-712, (1996).
Campana et al., “Prosaptide, a Peptide Derived from Prosaposin, Induces Motor Endplate Sprouting and Prevents Taxol Neuropathy”,Society for Neurosciences(Nov. 1995) 21:554.
Choi et al., “Behavioral Signs of Ongoing Pain and Cold Allodynia in a Rat Model of Neuropathic Pain”Pain 59:369-376, (1994).
Devor, “The pathophysiology of damaged peripheal nerves”Textbook of Pain, pp. 79-100, (1994).
France, “Chronic Pain and Depression”,J. Pain Symptom Manage 2(4):234-236 (1987).
Galbraith et al., “A System to measure Thermal Nociception”,J. Neurosci. Meth. 49:63-68, (1993).
Hefti et al., “Chronic Administration of Nerve Growth Factor and Other Neurotrophic Factors to the Brain” (1988) Neurobiol. of Aging 9:689-690.
Hong et al., Intercellular Adhesion Molecule-1 Expression Induced by Interleukin (IL)-1B or IL-1B Fragment is blocked by an IL-1 Receptor Antagonist and a Soluble IL-1 Receptor, Journal of Neuroimmunology 44(2):163-170 (Jun. 1993).
Jackowski, Neural Injury Repair: Hope for the Future as Barriers to Effective CNS Regeneration Become Clearer., British Journal of Neurosurgery 9:303-317 (1995).
Karagianis et al., “Synthesis of a potent antagonist of substance P by Replacing the CH2SCH3and the &agr;-carboxamide groups of the methionine at [Orn61-SP6-11by benzyl ester groups” (1993)Int. J. Peptide Protein Res.42:565-569.
Kim and Chung, “An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat”Pain50:355-363.
Kishore-Kumar et al., “Desipramine relieves postherpetic neuralgia”Clin. Pharmacol. Ther. 47(3):305-312, (1990).
Kotani, Ytasurori, et al., “A Hydrophilic Peptide Comprising 18 Amino Acid Residues of the Prosaposin Sequence Has Neurotrophic Activity In Vitro and In Vivo”,J. Neurochemistry, (May 1966) 66(5):2197-2200.
Kotani et al., Prosaposin in Facilitates Sciatic Nerve Regeneration In Vivo, Journal of Neurochemistry 66(5):2019-2025 (May 1996).
Malik and Calcutt “Diabetic Neuropathy”,Anesthesia: Biologic Foundations, Eds., pp. 869-877, (1997).
Max et al., “Amitriptyline relives diabetic neuropathy pain in patients with normal or depressed mood”,Neurology 37(4):589-596, (1987).
Max et al., “Amitriptyline, but not Lorazepam, relieves postherpetic neuralgia”,Neurology 38(9):1427-1432, (1988).
McMahon, Stephen B. et al., Peripheral neuropathies and neurotrophic facts: animal modes and clinical perspectives,Current Opinion in Neurobiology(1995) 5:616-624.
Merck Manual, 16th Ed. (1992) ed. Robert Berkow, Merck Research Laboratories, Rathway N.J., pp. 1416-1419.
Meyer et al. “Peripheral neural mechanisms of nociception”Textbook of Pain,pp. 13-44, 1994.
Myers, “The Pathogenesis of Neuropathic Pain” (May-Jun. 1995) Regional Anesthesia 20(3):173-184.
O'Brien et al., “Identification of the Neurotrophic Factor Sequence of Prosaposin” (May 1995)FASEB Jln.9:681-685.
O'Brien et al., “Indentification of Prosaposin as a Neurotrophic Factor” (1994)Proc. Natl. Acad. Sci USA91:9593-9596.
O'Brien and Kishimoto, “Saposin Proteins: Structure, Function, and Role in Human Lysosomal Storage Disorders” (1991)FASEB J.5:301-308.
Rudinger et al., “Peptide Hormones” (Jun. 1976) Ed. J.A. Parsons, Univ. Park Press, Baltimore, pp. 1-7.
Sano et al., “Protection by Prosaposin in Against Ischemia-Induced Learning Disability and Neuronal Loss,”Biochem. Biophys. Res. Commun.204 (2):994-1000 (1994).
Seltzer et al., “A novel behavioral mode of neuropathic pain disorders produced in rats by partial sciatic nerve injury”,Pain43:205-218, (1990).
Shir & Seltzer, “A-fibers mediate mechanical hyperesthesia and allodynia and C-fibers mediate thermal hyperalgesia in
Fuess & Davidenas
Hayes Robert C.
Kunz Gary L.
Regents of the University of CA
LandOfFree
Prosaposin-derived peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prosaposin-derived peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prosaposin-derived peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2447869